Form 4 for ADIL ADIAL PHARMACEUTICALS, INC.

Accepted 2021-12-01 00:00:00 ET · period of report 2021-11-29 · accession 0001213900-21-062729 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
M	2021-12-01	2021-11-29+	ADIL	Stilley William B. III	CEO, Dir, 10%	P - Purchase	$2.67	+20.6K	927.0K	+2%	+$55.0K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2021-11-30	P	A	10,600	$2.75	937,646	D	—	—	(F2) The price reported in Column 4 is a weighted average price. These 10,600 shares of common stock were purchased in multiple transactions at prices ranging from $2.5999 to $2.83, inclusive. The reporting person undertakes to provide to Adial Pharmaceuticals, Inc., any security holder of Adial Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4
2	Common	Common Stock	2021-11-29	P	A	10,000	$2.59	927,046	D	—	—	(F1) The price reported in Column 4 is a weighted average price. These 10,000 shares of common stock were purchased in multiple transactions at prices ranging from $2.54 to $2.60, inclusive. The reporting person undertakes to provide to Adial Pharmaceuticals, Inc., any security holder of Adial Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4